RxDoctor Payments DataLook up a doctor →

Christopher Fisher, MD

Pain Medicine · Las Vegas, NVNPI 1396944740

Payments from drug & device makers

$13,060in general payments, 2019–2025

Across 681 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Scilex Pharmaceuticals Inc.$2K
  • Collegium Pharmaceutical, Inc.$2K
  • Forte Bio-pharma LLC$1K
  • IBSA Pharma Inc.$951
  • Redhill Biopharma Inc.$885
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$8306%
  • Food & beverage$12,23094%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,060 in reported general payments places this provider in the 80th percentile of 101 pain medicine providers in Nevada.

See all pain medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$120,152
Medicare patients
271
Services billed
1,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide16$37,521
BelbucaBuprenorphine Hcl25$21,650
ZtlidoLidocaine17$16,070
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen104$14,879
LinzessLinaclotide14$7,676
Lidocaine29$5,679
MovantikNaloxegol Oxalate12$5,522
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen183$4,766
Pregabalin46$2,972
Oxycodone Hcl118$2,893
Diclofenac Sodium18$2,715
Gabapentin236$1,544
Tramadol Hcl ErTramadol Hcl24$1,452
Baclofen44$952
Cyclobenzaprine Hcl153$923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$2,169$37,52116 claims
Collegium Pharmaceutical, Inc.Belbuca$1,739$21,65025 claims
Scilex Pharmaceuticals Inc.Ztlido$1,757$16,07017 claims
AbbVieLinzess$361$7,67614 claims
Redhill Biopharma Inc.Movantik$885$5,52212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 pain medicine providers in Nevada.

Other pain medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →